Interaction Checker

Tesamorelin interactions

Tesamorelin (Egrifta) has 55 documented interactions across the FDA labels and fact sheets we index: 0 major, 23 moderate, 32 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Moderate interactions (23)

  • Azelastine and fluticasoneantihistamineModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • BeclomethasonecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • BetamethasonecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • BudesonidecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • Budesonide and formoterolcorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • CiclesonidecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • ClobetasolcorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • DeflazacortcorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • DesonidecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • DexamethasonecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • FludrocortisonecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • FlunisolidecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • FluocinonidecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • FluticasonecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • Fluticasone and salmeterolcorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • HalobetasolcorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • HydrocortisonecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • MethylprednisolonecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • MometasonecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • Olopatadine and mometasoneantihistamineModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • PrednisolonecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • PrednisonecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

  • TriamcinolonecorticosteroidModerate

    Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (Tesamorelin label, Drug interactions)

Minor mentions (32)

  • BrivaracetamanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • Cannabidiol (prescription)anticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • CarbamazepineanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • CenobamateanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • ClobazambenzodiazepineMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • ClonazepambenzodiazepineMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • CyclosporineimmunosuppressantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • Divalproex (valproate)anticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • EslicarbazepineanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • EthosuximideanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • Ezetimibe and simvastatinstatinMinor

    Cytochrome P450-Metabolized Drugs Co-administration of tesamorelin with simvastatin, a CYP3A substrate had no significant impact on the pharmacokinetics profiles of simvastatin in healthy subjects [see Clinical Pharmacology ( 12.3 )] . (Tesamorelin label, Drug interactions)

  • FelbamateanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • FosphenytoinanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • GabapentinanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • LacosamideanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • LamotrigineanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • LevetiracetamanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • MethsuximideanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • OxcarbazepineanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • PerampanelanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • PhenobarbitalbarbiturateMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • Phentermine and topiramateCNS stimulantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • PhenytoinanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • PregabalinanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • PrimidoneanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • RufinamideanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • SimvastatinstatinMinor

    Cytochrome P450-Metabolized Drugs Co-administration of tesamorelin with simvastatin, a CYP3A substrate had no significant impact on the pharmacokinetics profiles of simvastatin in healthy subjects [see Clinical Pharmacology ( 12.3 )] . (Tesamorelin label, Drug interactions)

  • TiagabineanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • TopiramateanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • Valproic acidanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • VigabatrinanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

  • ZonisamideanticonvulsantMinor

    These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (Tesamorelin label, Drug interactions)

Check Tesamorelin against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.